Re-inspection fees
This article was originally published in The Gray Sheet
Executive Summary
The new user fee request included in FDA's FY 2007 budget proposal requiring device and drug makers to pay for re-inspections of facilities that fail to comply with good manufacturing practices would not only allow FDA to make the best use of its limited resources, but it would encourage device firms to be in compliance, according to Steven Niedelman, the agency's assistant commissioner for regulatory affairs (1"The Gray Sheet" Feb. 13, 2006, p. 6). "Every time we have to do a re-inspection, we don't get to another [firm] that needs [primary inspection]," Niedelman said in an interview. FDA is interested in hearing from stakeholders on the issue, he said. In Feb. 16 written testimony to the House Appropriations subcommittee overseeing FDA funding, AdvaMed said that "any additional fees must be...associated with clearly identified increased performance to benefit the fee payer above and beyond current performance"...
You may also be interested in...
FDA Budget Request Proposes New User Fee For Facility Reinspections
FDA is proposing a new mandatory user fee that would require device and drug manufacturers to pay for reinspections of manufacturing facilities cited for violations
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.